Psilocybin fungi microdose treatment in major depressive disorder: a case report

Area of Science:

• Neuroscience
• Psychiatry
• Pharmacology

Background:

• Major depressive disorder (MDD) has a high prevalence and significant global impact.
• Current MDD treatments have a 15-30% non-response rate and potential adverse effects like apathy.
• Psilocybin treatment may allow for reduced dosages of conventional psychotropic drugs and offer emotional/behavioral benefits.

Purpose of the Study:

• To present a case study on the self-administration of psilocybin microdoses in a patient diagnosed with MDD.
• To evaluate the efficacy and safety of psilocybin microdosing as an adjunct or alternative to traditional MDD therapies.
• To explore the impact of psilocybin microdosing on emotional, behavioral, and social functioning in an MDD patient.

Main Methods:

• A 19-year-old patient with MDD was monitored for 7 months during psilocybin microdose self-administration.
• Intervention involved patient counseling on autonomy and risk reduction for psilocybin use.
• Weekly evaluations included clinical history, laboratory tests, and the Hamilton Depression Scale.

Main Results:

• The patient achieved complete symptomatic remission of MDD.
• Conventional pharmacological treatment was successfully suspended without discontinuation symptoms.
• Significant improvements were observed in communication, social interaction, and overall well-being.

Conclusions:

• Psilocybin microdosing appears to be a promising therapeutic tool for managing major depressive disorder.
• This case suggests potential benefits in achieving remission and enhancing quality of life.
• Further rigorous scientific studies are necessary to validate these findings and establish psilocybin's role in depression treatment.